These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33519461)

  • 1. Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats.
    Zhang W; Liu J; Fu Y; Ji H; Fang Z; Zhou W; Fan H; Zhang Y; Liao Y; Yang T; Wang X; Yuan W; Chen X; Dong YF
    Front Pharmacol; 2020; 11():600953. PubMed ID: 33519461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
    Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
    Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway.
    Wu M; Guo Y; Wu Y; Xu K; Lin L
    Front Pharmacol; 2021; 12():696472. PubMed ID: 34135764
    [No Abstract]   [Full Text] [Related]  

  • 4. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.
    Moraña-Fernández S; Vázquez-Abuín X; Aragón-Herrera A; Anido-Varela L; García-Seara J; Otero-García Ó; Rodríguez-Penas D; Campos-Toimil M; Otero-Santiago M; Rodrigues A; Gonçalves A; Pereira Morais J; Alves IN; Sousa-Mendes C; Falcão-Pires I; González-Juanatey JR; Feijóo-Bandín S; Lago F
    Biochem Pharmacol; 2024 Dec; 230(Pt 1):116571. PubMed ID: 39424202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.
    Croteau D; Qin F; Chambers JM; Kallick E; Luptak I; Panagia M; Pimentel DR; Siwik DA; Colucci WS
    JACC Basic Transl Sci; 2020 Sep; 5(9):916-927. PubMed ID: 33015414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Passive Leg Movement Prevents Against the Development of Heart Failure With Preserved Ejection Fraction in Rats.
    Liu J; Ji XX; Fu Y; Zhang WC; Ji HF; Liu JW; Cheng XS; Dong YF
    Front Cardiovasc Med; 2021; 8():655009. PubMed ID: 33969019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
    Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
    Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis.
    Fu S; Xu Z; Lin B; Chen J; Huang Q; Xu Y; Xu A; Chen Y; Tang Y
    Front Med (Lausanne); 2021; 8():657067. PubMed ID: 34235161
    [No Abstract]   [Full Text] [Related]  

  • 12. Sacubitril/Valsartan Improves Cardiac Function in Dialysis Patients.
    Armaly Z; Saffouri A; Kordahji H; Hamzeh M; Bishouty E; Matar N; Zaher M; Jabbour A; Qarawani D
    Cureus; 2024 Jun; 16(6):e63360. PubMed ID: 39070454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains.
    Korshunov VA; Quinn B; Faiyaz A; Ahmed R; Sowden MP; Doyley MM; Berk BC
    Br J Pharmacol; 2019 Aug; 176(15):2795-2807. PubMed ID: 31077344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
    Nishio H; Ishii A; Yamada H; Mori KP; Kato Y; Ohno S; Handa T; Sugioka S; Ishimura T; Ikushima A; Inoue Y; Minamino N; Mukoyama M; Yanagita M; Yokoi H
    Nephrol Dial Transplant; 2023 Oct; 38(11):2517-2527. PubMed ID: 37202215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data.
    Cuthbert JJ; Pellicori P; Clark AL
    Ther Clin Risk Manag; 2020; 16():715-726. PubMed ID: 32848403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China.
    Wu Y; Tian S; Rong P; Zhang F; Chen Y; Guo X; Zhou B
    Front Pharmacol; 2020; 11():1101. PubMed ID: 32792946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan alleviates myocardial infarction-induced inflammation in mice by promoting M2 macrophage polarisation via regulation of PI3K/Akt pathway.
    Jin N; Qiu Y; Zhang K; Fang Y; Qu S; Zhu L; Li H; Nie B
    Acta Cardiol; 2024 Sep; 79(7):768-777. PubMed ID: 39257342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation.
    Suzuki J; Kaji K; Nishimura N; Kubo T; Tomooka F; Shibamoto A; Iwai S; Tsuji Y; Fujinaga Y; Kitagawa K; Namisaki T; Akahane T; Yoshiji H
    Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes.
    Xiao F; Wang L; Liu M; Chen M; He H; Jia Z; Zhang L; Yang Y; Hu Q; Hong M; Zhang H
    Arch Biochem Biophys; 2022 Nov; 730():109415. PubMed ID: 36179911
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.